Apple results top estimates as iPhone sales shine amid China demand rebound
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL) shares jumped 10.1% after the clinical-stage biotechnology company reported positive Phase 1 data for its Alzheimer’s disease drug candidate and provided updates on its development pipeline.
The company announced favorable safety and efficacy results from a Phase 1 trial of VG-3927, its oral small molecule TREM2 agonist for potential Alzheimer’s treatment. VG-3927 demonstrated a positive safety profile and achieved up to 50% reduction of a key biomarker in cerebrospinal fluid, showing strong target engagement. Vigil plans to advance a 25 mg once-daily dose into Phase 2 trials starting in Q3 2025.
For Q4 2024, Vigil reported an adjusted loss per share of $0.57, missing analyst estimates by $0.03.
"We are entering 2025 with strong momentum, driven by significant progress in the development of our TREM2 programs, VG-3927 and iluzanebart," said CEO Ivana Magovčević-Liebisch. She added that VG-3927 "has the potential to provide a novel, next-generation therapy for Alzheimer’s disease."
Vigil ended 2024 with $97.8 million in cash and equivalents, which it expects will fund operations into 2026. R&D expenses rose 2.3% YoY to $62.3 million for full-year 2024.
The company is also advancing iluzanebart for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), with final Phase 2 data expected in Q2 2025. Vigil aims to pursue an accelerated approval pathway for this rare neurodegenerative disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.